The Potency of Luliconazole against Clinical and Environmental Isolates of Aspergillus flavus

Introduction and Objectives: Luliconazole, a new imidazole antifungal, is currently confirmed for the topical treatment of some superficial and cutaneous mycosis. The in vitro activities of luliconazole has also shown against some molds and yeasts. Aspergillus flavus is an important opportunistic fungus cause of Aspergillosis. Amphotericin B was as Gold standard antifungal agent for invasive fungal infection for more than 5 decades. However, it replaced by some azole antifungals. The aim of the present study was to evaluate the effects of luliconazole in comparison with amphotericin B, voriconazole, and caspofungin on clinical and environmental isolates of A. flavus. Materials and Methods: Thirty-eight isolates of A. flavus (20 clinical and 18 environmental) were collected from Ahvaz, Iran. Based on PCR-sequencing of β-tubulin ribosomal DNA gene all isolates were detected as A. flavus. All isolates tested against luliconazole, voriconazole, amphotericin B and caspofungin using by CLSI M38-A2 guidelines. Minimum inhibitory concentration (MIC), MIC50, MIC90 and MICGM were calculated for both environmental and clinical isolates. Results: Luliconazole with MICGM 0.0024 showed potent activity against A. flavus isolates and followed by voriconazole inhibited 95% of isolates at 1g/ml. 25% and 11.1% of the clinical and environmental isolates of A. flavus, respectively, were displayed resistant to caspofungin. All isolates were found to be resistant to amphotericin B. Also, we did not see any statistically significant difference between clinical and environmental strain and resistant to both voriconazole (p > 0.11) and caspofungin (p > 0.13).Conclusions: Our results confirm that in vitro activities luliconazole is useful on A. flavus vs another antifungal studied.

کلیدواژه ها:

Luliconazole ، Amphotericin B ، Voriconazole ، Caspofungin ، Aspergillus flavus